Affiliation: Institute of Cancer Research
- Targeted approaches to childhood cancer: progress in drug discovery and developmentSteffen Hirsch
The Royal Marsden NHS Foundation Trust, Children and Young People s Unit, Sutton, Surrey, SM2 5PT, UK 44 0 20 8915 6161
Expert Opin Drug Discov 10:483-95. 2015..Drug development in paediatric oncology has specific requirements with regard to the patient population and the regulatory background and presents several unique challenges that need addressing...
- Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experienceLucas Moreno
Children and Young People s Unit, The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
Pediatr Blood Cancer 60:1135-40. 2013..The aim of this study was to identify the nature and severity of late complications of metastatic neuroblastoma survivors included in the ENSG5 clinical trial...
- How can attrition rates be reduced in cancer drug discovery?Lucas Moreno
Paediatric Drug Development, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UK 44 0 208 661 3678 44 0 208 661 3617
Expert Opin Drug Discov 8:363-8. 2013..Finally, there is a need for increased collaboration to combine the unique strengths between industry, academia and regulators to ensure that the needs of all stakeholders are met...
- Preclinical drug development for childhood cancerLucas Moreno
The Royal Marsden NHS Foundation Trust, Children and Young People s Unit, Sutton, Surrey, UK
Expert Opin Drug Discov 6:49-64. 2011..More effective drugs are needed to treat poor prognosis paediatric malignancies. Development of anticancer agents for childhood cancers faces several unique challenges compared with their adult counterparts...
- Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experienceDaniel A Morgenstern
Pediatric Drug Development Unit, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust Pediatric Drug Development Team, Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, Sutton Pediatric Oncology Department, Great Ormond Street Hospital Institute of Child Health, University College London, London, UK
J Pediatr Hematol Oncol 36:218-23. 2014..Continued expansion of the portfolio is needed ultimately to improve the outcomes for those with resistant disease. ..
- Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk NeuroblastomaDominik Schrey
Children and Young People s Unit Department of Nuclear Medicine and PET CT, The Royal Marsden NHS Foundation Trust Divisions of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK Clinical Research Programme, Spanish National Cancer Research Centre CNIO, Madrid, Spain
J Pediatr Hematol Oncol 37:e150-3. 2015..It is therefore proposed to develop stratification criteria for those patients very unlikely to benefit from a plethora of additional lines of treatment, but might benefit from introduction of novel agents. ..
- A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK studyLucas Moreno
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom CNIO, Madrid, Spain
Clin Cancer Res 21:267-73. 2015....
- MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistanceGiuseppe Barone
The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom
Curr Drug Targets 15:114-23. 2014..In conclusion, targeting the interaction between p53 and its main negative regulator MDM2 represents a major new therapeutic approach in poor prognosis paediatric malignancies without p53 mutations. ..